Get help with any kind of assignment - from a high school essay to a PhD dissertation
Article #1 A research by Antonanzas, Rive, Badenas, Gomez-Lus and Guilhaume (2006) determined the price of taking care of an individual with Alzheimer's disease (AD) from Spain. The researchers set out to see whether the advantages of placing a moderate to severe Alzheimer's patient on Memantine, a pharmaceutical medication approved for use with AD patients and also help increase their freedom, outweighed the cost of the drug and the price of conventional community maintenance from Spain (p.137). To assess the cost of care for an AD patient, a new stochastic model was made. This model utilized whether a participant has been categorized as dependent or individual at the onset of the analysis and the intensity of the patients AD to set the participants into seven health conditions. The Memantine was distributed within a double blind study using 252 participants. Considering that Memantine is only approved for using moderately severe to severe AD patients, researchers picked 41 percent of the participants whom were diagnosed with moderately severe AD and 59 percent whom were believed to suffer from severed AD. The drugs/ placebos were administered for 1 year of this two-year analysis. The quantity of time spent being separate has been quantified as well as the expense of maintenance for all participants (Antonanzas, Rive, Badenas, Gomez-Lus, & Guilhaume, 2006, p.137-139). In the conclusion of the two-year analysis, it was discovered that people who were given the placebo and got the regular maintenance in Spain were independent for 6 weeks and had a mean price of care of 24,700 euros ($33,777.25). With the use of Memantine, there was a liberty of 8.5 weeks and a price of maintenance of 24,000 euros ($32,731.00). These costs and length of liberty were found with the model made for the study (Antonanzas et al., 2006,...